Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-09, Stock:ABBV, The news for the past five days is as follows:
2018-01-02: NEWS1: Notable Tuesday Option Activity: FDX, WM, ABBV.NEWS2: The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S.NEWS3: 3 Best Big Pharma Stocks to Buy for 2018.NEWS4: 3 Best Big Pharma Stocks to Buy for 2018.NEWS5: The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche&apos;s, AstraZeneca and Novo-Nordisk A/S.
2018-01-03: NEWS1: Top 4 Marijuana Stocks to Watch.NEWS2: Stocks With Rising Relative Price Strength: Grifols.
2018-01-04: NEWS1: 3 Large-Cap Pharma Stocks to Watch Out for This New Year.NEWS2: Biggest Blockbuster Drugs of All Time.NEWS3: MTUM, BA, ABBV, ADBE: ETF Inflow Alert.NEWS4: Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?.NEWS5: ABBV Crosses Above Average Analyst Target.NEWS6: Blizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports.NEWS7: Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?.NEWS8: 18 Reasons I Like Biotech Stocks in 2018.NEWS9: 18 Reasons I Like Biotech Stocks in 2018.
2018-01-05: NEWS1: Why AbbVie Could See a Big Rise in Its Net Profit Margin in Fiscal 2017.NEWS2: Spiros Segalas Buys 3 New Stocks in 4th Quarter.NEWS3: Why AbbVie Is Expected to Report Robust Revenue Growth for 2017.NEWS4: Will J&J (JNJ) Continue to Tread Growth Path This Year?.NEWS5: AbbVie and Peers: Analyst Recommendations in December.NEWS6: Key Biosimilar Approvals in 2017: Progress Report.NEWS7: Biotech: The Tide Is Turning.NEWS8: Will J&J (JNJ) Continue to Tread Growth Path This Year?.NEWS9: Key Biosimilar Approvals in 2017: Progress Report.NEWS10: 3 Large-Cap Pharma Stocks to Watch Out for This New Year.
2018-01-08: NEWS1: Cramer&apos;s lightning round: Mercadolibre is even better than eBay was.NEWS2: Cramer's lightning round: Mercadolibre is even better than eBay was.NEWS3: Galapagos Reports Topline Data From Osteoarthritis Study.NEWS4: Understanding AbbVie’s Positive Upadacitinib Data for Atopic Dermatitis.NEWS5: US STOCKS-Wall St new year rally pauses as healthcare, bank stocks weigh.NEWS6: Galapagos Reports Topline Data From Osteoarthritis Study.NEWS7: Why AbbVie’s Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis.NEWS8: AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis.NEWS9: What Upadacitinib Did for AbbVie in 2017.NEWS10: This Is Expected to Boost AbbVie’s Growth Prospects.NEWS11: Why Humira Is Still a Solid Growth Driver for AbbVie in 2018.NEWS12: How Increasing Biologic Penetration Could Boost AbbVie’s Revenues.

Answer: Rise